William Blair and BDA advise CMC Biologics on sale to Asahi Glass

William Blair acted as the exclusive financial advisor to CMC Biologics, a portfolio company of Monitor Clipper Partners and European Equity Partners, in connection with its sale to Asahi Glass. William Blair advised on the transaction in conjunction with its Asian affiliate, BDA Partners. This transaction was signed on December 15, 2016, and closed on February 1, 2017.

Transaction Highlights

Deep relationships and sector expertise: CMC was attracted to William Blair’s highly relevant pharmaceutical contract development and manufacturing transaction experience, deep sector knowledge, and ability to identify and effectively engage with the most likely acquirers. By drawing on its extensive knowledge of the CDMO sector, William Blair was able to successfully position the investment merits of the opportunity.

Global execution expertise: William Blair’s proven ability to deliver strong outcomes by coordinating highly competitive global processes was crucial. William Blair’s sales process produced a strong competitive dynamic, attractive valuation, and favorable economic and purchase agreement terms.

Trusted guidance for long-term growth: William Blair’s advisory of CMC has entailed multiple financing rounds, including Monitor Clipper Partners’ investment in 2008. Furthermore, for more than a decade, William Blair has been a trusted advisor to management and its shareholders through CMC’s most significant transactions, including the acquisition of its Seattle manufacturing facility from Eli Lilly.